DexCom
DXCM
508 hedge funds and large institutions have $19.9B invested in DexCom in 2019 Q4 according to their latest regulatory filings, with 118 funds opening new positions, 160 increasing their positions, 167 reducing their positions, and 29 closing their positions.
307% more first-time investments, than exits
New positions opened: 118 | Existing positions closed: 29
71% more funds holding in top 10
Funds holding in top 10: 7 → 12 (+5)
47% more capital invested
Capital invested by funds: $13.6B → $19.9B (+$6.33B)
20% more funds holding
Funds holding: 423 → 508 (+85)
4% less repeat investments, than reductions
Existing positions increased: 160 | Existing positions reduced: 167
1.2% less ownership
Funds ownership: 398.98% → 397.78% (-1.2%)
52% less call options, than puts
Call options by funds: $145M | Put options by funds: $299M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
+$201M |
| 2 |
Morgan Stanley
New York
|
+$198M |
| 3 |
AI
Alphabet Inc
Mountain View,
California
|
+$132M |
| 4 |
Renaissance Technologies
New York
|
+$122M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$110M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$323M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$170M |
| 3 |
Jennison Associates
New York
|
-$110M |
| 4 |
Coatue Management
New York
|
-$67.6M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$63.9M |
DXCM Hedge Fund Activity: Q4 2019 in Review
508 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q4 2019, worth a combined $19.9B — up 47% from $13.6B a quarter earlier.
Buyers outnumbered sellers: 118 funds opened new DXCM positions and 29 closed out — a net gain of 89 holders — while 160 added to existing stakes and 167 trimmed.
The largest buyer was Lone Pine Capital, opening a new position worth an estimated $201M. The largest seller was T. Rowe Price Associates, cutting an estimated $323M.
- 508 institutional investors held DexCom (DXCM) as of Q4 2019, up from 423 in Q3 2019.
- Funds reported $19.9B of DexCom stock for Q4 2019, up 47% quarter-over-quarter.
- 118 funds opened new DexCom positions in Q4 2019 and 29 closed out, a net change of +89 holders.
- The largest DexCom buyer in Q4 2019 was Lone Pine Capital, an estimated $201M added.
- The largest DexCom seller in Q4 2019 was T. Rowe Price Associates, an estimated $323M sold.
Based on aggregated 13F filings for Q4 2019.